{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:00:55Z","timestamp":1793962855024,"version":"4.8.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasing public health problem, affecting one third of the global population. Contrary to conventional wisdom, MAFLD is not exclusive to obese or overweight individuals. Epidemiological studies have revealed a remarkable prevalence among healthy weight individuals, leading investigations into the genetic, lifestyle, and dietary factors that contribute to the development of MAFLD in this population. This shift in perspective requires reconsideration of preventive strategies, diagnostic criteria and therapeutic approaches tailored to address the unique characteristics of MAFLD healthy weight individuals. It also underscores the importance of widespread awareness and education, within the medical community and among the general population, to promote a more inclusive understanding of liver metabolic disorders. With this review, we aim to provide a comprehensive exploration of MAFLD in healthy weight individuals, encompassing epidemiological, pathophysiological, and clinical aspects.<\/jats:p>","DOI":"10.1007\/s12072-024-10662-w","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T06:26:13Z","timestamp":1721888773000},"page":"884-896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Metabolic dysfunction associated fatty liver disease in healthy weight individuals"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-8048","authenticated-orcid":false,"given":"Nahum","family":"M\u00e9ndez-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem Pieter","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lammert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"issue":"10319","key":"10662_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399(10319):61\u2013116. https:\/\/doi.org\/10.1016\/S0140-6736(21)01701-3. (Epub 2021\/12\/06)","journal-title":"Lancet"},{"issue":"5","key":"10662_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s12072-023-10568-z","volume":"17","author":"K Vaz","year":"2023","unstructured":"Vaz K, Clayton-Chubb D, Majeed A, Lubel J, Simmons D, Kemp W, et al. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatol Int 2023;17(5):1082\u20131097. https:\/\/doi.org\/10.1007\/s12072-023-10568-z. (Epub 20230809)","journal-title":"Hepatol Int"},{"issue":"4","key":"10662_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77(4):1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004. (Epub 2023\/01\/11)","journal-title":"Hepatology"},{"issue":"3","key":"10662_CR4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jceh.2022.12.005","volume":"13","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Paik JM, Henry L, Yang J, Fernandes G, Stepanova M, et al. The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States. J Clin Exp Hepatol 2023;13(3):454\u2013467. https:\/\/doi.org\/10.1016\/j.jceh.2022.12.005. (Epub 2023\/05\/30)","journal-title":"J Clin Exp Hepatol"},{"issue":"8","key":"10662_CR5","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/MEG.0000000000000641","volume":"28","author":"S van Meer","year":"2016","unstructured":"van Meer S, van Erpecum KJ, Sprengers D, Klumpen HJ, Jansen PL, Ijzermans JN, et al. Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. Eur J Gastroenterol Hepatol 2016;28(8):955\u2013962. https:\/\/doi.org\/10.1097\/MEG.0000000000000641. (Epub 2016\/05\/20)","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"10662_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00535-023-02021-7","volume":"58","author":"H Crane","year":"2023","unstructured":"Crane H, Gofton C, Sharma A, George J. MAFLD: an optimal framework for understanding liver cancer phenotypes. J Gastroenterol 2023;58(10):947\u2013964. https:\/\/doi.org\/10.1007\/s00535-023-02021-7. (Epub 20230720)","journal-title":"J Gastroenterol"},{"issue":"1","key":"10662_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039. (Epub 2020\/04\/12)","journal-title":"J Hepatol"},{"issue":"5","key":"10662_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/hepr.13706","volume":"52","author":"T Kawaguchi","year":"2022","unstructured":"Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 2022;52(5):422\u2013432. https:\/\/doi.org\/10.1111\/hepr.13706. (Epub 20210917)","journal-title":"Hepatol Res"},{"issue":"6","key":"10662_CR9","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79(6):1542\u20131556. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003. (Epub 20230624)","journal-title":"J Hepatol"},{"issue":"1","key":"10662_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12072-022-10436-2","volume":"17","author":"AD Dao","year":"2023","unstructured":"Dao AD, Nguyen VH, Ito T, Cheung R, Nguyen MH. Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States. Hepatol Int 2023;17(1):225\u2013236. https:\/\/doi.org\/10.1007\/s12072-022-10436-2. (Epub 20221029)","journal-title":"Hepatol Int"},{"issue":"10","key":"10662_CR11","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.cgh.2022.11.019","volume":"21","author":"J Ha","year":"2023","unstructured":"Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2023;21(10):2496-507e5. https:\/\/doi.org\/10.1016\/j.cgh.2022.11.019. (Epub 2022\/11\/29)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"22","key":"10662_CR12","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313(22):2263\u20132273. https:\/\/doi.org\/10.1001\/jama.2015.5370. (Epub 2015\/06\/10)","journal-title":"JAMA"},{"issue":"3","key":"10662_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ecl.2023.02.003","volume":"52","author":"C Gofton","year":"2023","unstructured":"Gofton C, Clark-Dickson M, George J. Lean metabolic-associated fatty liver disease. Endocrinol Metab Clin North Am 2023;52(3):431\u2013444. https:\/\/doi.org\/10.1016\/j.ecl.2023.02.003. (Epub 20230321)","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"10662_CR14","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/ijms22084156","volume":"22","author":"Y Sakurai","year":"2021","unstructured":"Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci 2021;22(8):4156. https:\/\/doi.org\/10.3390\/ijms22084156. (Epub 20210416)","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10662_CR15","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/hep.32047","volume":"74","author":"S Vilarinho","year":"2021","unstructured":"Vilarinho S, Ajmera V, Zheng M, Loomba R. Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD. Hepatology 2021;74(4):2241\u20132250. https:\/\/doi.org\/10.1002\/hep.32047. (Epub 2021\/07\/08)","journal-title":"Hepatology"},{"issue":"3","key":"10662_CR16","first-page":"389","volume":"74","author":"B Vos","year":"2011","unstructured":"Vos B, Moreno C, Nagy N, Fery F, Cnop M, Vereerstraeten P, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg 2011;74(3):389\u2013394 (Epub 2011\/11\/23)","journal-title":"Acta Gastroenterol Belg"},{"issue":"8","key":"10662_CR17","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","volume":"21","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol 2023;21(8):1978\u20131991. https:\/\/doi.org\/10.1016\/j.cgh.2023.04.015. (Epub 2023\/05\/01)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10662_CR18","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.cgh.2017.04.045","volume":"15","author":"AL Fracanzani","year":"2017","unstructured":"Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol 2017;15(10):1604\u20131611. https:\/\/doi.org\/10.1016\/j.cgh.2017.04.045. (Epub 2017\/05\/31)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10662_CR19","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/j.1440-1746.2012.07222.x","volume":"27","author":"CJ Liu","year":"2012","unstructured":"Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012;27(10):1555\u20131560. https:\/\/doi.org\/10.1111\/j.1440-1746.2012.07222.x. (Epub 2012\/06\/30)","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10662_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/gutjnl-2021-324162","volume":"71","author":"S Francque","year":"2022","unstructured":"Francque S, Wong VW. NAFLD in lean individuals: not a benign disease. Gut 2022;71(2):234\u2013236. https:\/\/doi.org\/10.1136\/gutjnl-2021-324162. (Epub 20210312)","journal-title":"Gut"},{"issue":"6","key":"10662_CR21","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.aohep.2023.101138","volume":"28","author":"MM Ram\u00edrez-Mej\u00eda","year":"2023","unstructured":"Ram\u00edrez-Mej\u00eda MM, Qi X, Abenavoli L, Romero-G\u00f3mez M, Eslam M, M\u00e9ndez-S\u00e1nchez N. Metabolic dysfunction: the silenced connection with fatty liver disease. Ann Hepatol 2023;28(6):101138. https:\/\/doi.org\/10.1016\/j.aohep.2023.101138. (Epub 20230717)","journal-title":"Ann Hepatol"},{"issue":"1","key":"10662_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0038-1677517","volume":"39","author":"R Younes","year":"2019","unstructured":"Younes R, Bugianesi E. NASH in lean individuals. Semin Liver Dis 2019;39(1):86\u201395. https:\/\/doi.org\/10.1055\/s-0038-1677517. (Epub 20190117)","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10662_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11154-020-09621-1","volume":"22","author":"S Maier","year":"2021","unstructured":"Maier S, Wieland A, Cree-Green M, Nadeau K, Sullivan S, Lanaspa MA, et al. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord 2021;22(2):351\u2013366. https:\/\/doi.org\/10.1007\/s11154-020-09621-1. (Epub 20210103)","journal-title":"Rev Endocr Metab Disord"},{"key":"10662_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-023-00620-9","author":"MM Ram\u00edrez-Mej\u00eda","year":"2023","unstructured":"Ram\u00edrez-Mej\u00eda MM, M\u00e9ndez-S\u00e1nchez N. What is in a name: from NAFLD to MAFLD and MASLD\u2014unraveling the complexities and implications. Curr Hepatol Rep 2023. https:\/\/doi.org\/10.1007\/s11901-023-00620-9","journal-title":"Curr Hepatol Rep"},{"issue":"2","key":"10662_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cld.2023.01.011","volume":"27","author":"A Duseja","year":"2023","unstructured":"Duseja A, De A, Wong V. Special population: lean nonalcoholic fatty liver disease. Clin Liver Dis 2023;27(2):451\u2013469. https:\/\/doi.org\/10.1016\/j.cld.2023.01.011. (Epub 20230226)","journal-title":"Clin Liver Dis"},{"issue":"7","key":"10662_CR26","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/jbmr.3713","volume":"34","author":"LJM Alferink","year":"2019","unstructured":"Alferink LJM, Trajanoska K, Erler NS, Schoufour JD, de Knegt RJ, Ikram MA, et al. Nonalcoholic fatty liver disease in the rotterdam study: about muscle mass, sarcopenia, fat mass, and fat distribution. J Bone Miner Res 2019;34(7):1254\u20131263. https:\/\/doi.org\/10.1002\/jbmr.3713","journal-title":"J Bone Miner Res"},{"key":"10662_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.hnm.2023.200210","volume":"33","author":"S Bansal","year":"2023","unstructured":"Bansal S, Vachher M, Arora T, Kumar B, Burman A. Visceral fat: a key mediator of NAFLD development and progression. Hum Nutr Metab 2023;33: 200210. https:\/\/doi.org\/10.1016\/j.hnm.2023.200210","journal-title":"Hum Nutr Metab"},{"issue":"6","key":"10662_CR28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s12072-019-09996-7","volume":"13","author":"JA Kim","year":"2019","unstructured":"Kim JA, Choi KM. Sarcopenia and fatty liver disease. Hepatol Int 2019;13(6):674\u2013687. https:\/\/doi.org\/10.1007\/s12072-019-09996-7. (Epub 20191108)","journal-title":"Hepatol Int"},{"issue":"2","key":"10662_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/cld.900","volume":"16","author":"AA Li","year":"2020","unstructured":"Li AA, Kim D, Ahmed A. Association of sarcopenia and NAFLD: an overview. Clin Liver Dis (Hoboken) 2020;16(2):73\u201376. https:\/\/doi.org\/10.1002\/cld.900. (Epub 20200904)","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10662_CR30","doi-asserted-by":"publisher","first-page":"1217249","DOI":"10.3389\/fendo.2023.1217249","volume":"14","author":"M Chen","year":"2023","unstructured":"Chen M, Cao Y, Ji G, Zhang L. Lean nonalcoholic fatty liver disease and sarcopenia. Front Endocrinol (Lausanne) 2023;14:1217249. https:\/\/doi.org\/10.3389\/fendo.2023.1217249. (Epub 20230623)","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10662_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10753-021-01559-z","volume":"45","author":"L Al-Mansoori","year":"2022","unstructured":"Al-Mansoori L, Al-Jaber H, Prince MS, Elrayess MA. Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance. Inflammation 2022;45(1):31\u201344. https:\/\/doi.org\/10.1007\/s10753-021-01559-z","journal-title":"Inflammation"},{"issue":"3","key":"10662_CR32","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ecl.2023.01.004","volume":"52","author":"TM Barber","year":"2023","unstructured":"Barber TM, Hanson P, Weickert MO. Metabolic-associated fatty liver disease and the gut microbiota. Endocrinol Metab Clin N Am 2023;52(3):485\u2013496. https:\/\/doi.org\/10.1016\/j.ecl.2023.01.004. (Epub 20230301)","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"1","key":"10662_CR33","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","volume":"11","author":"G Lee","year":"2020","unstructured":"Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S, et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun 2020;11(1):4982. https:\/\/doi.org\/10.1038\/s41467-020-18754-5. (Epub 20201005)","journal-title":"Nat Commun"},{"issue":"7","key":"10662_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41575-023-00771-6","volume":"20","author":"O Pabst","year":"2023","unstructured":"Pabst O, Hornef MW, Schaap FG, Cerovic V, Clavel T, Bruns T. Gut-liver axis: barriers and functional circuits. Nat Rev Gastroenterol Hepatol 2023;20(7):447\u2013461. https:\/\/doi.org\/10.1038\/s41575-023-00771-6. (Epub 20230421)","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10662_CR35","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","volume":"34","author":"H Tilg","year":"2022","unstructured":"Tilg H, Adolph TE, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab 2022;34(11):1700\u20131718. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.017. (Epub 20221007)","journal-title":"Cell Metab"},{"issue":"5","key":"10662_CR36","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1053\/j.gastro.2012.01.034","volume":"142","author":"S Pendyala","year":"2012","unstructured":"Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 2012;142(5):1100\u20131.e2. https:\/\/doi.org\/10.1053\/j.gastro.2012.01.034. (Epub 20120208)","journal-title":"Gastroenterology"},{"key":"10662_CR37","doi-asserted-by":"publisher","first-page":"1003755","DOI":"10.3389\/fmicb.2022.1003755","volume":"13","author":"Y Xia","year":"2022","unstructured":"Xia Y, Ren M, Yang J, Cai C, Cheng W, Zhou X, et al. Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: correlation and causality. Front Microbiol 2022;13:1003755. https:\/\/doi.org\/10.3389\/fmicb.2022.1003755. (Epub 20220920)","journal-title":"Front Microbiol"},{"issue":"8","key":"10662_CR38","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/nu11081712","volume":"11","author":"Y Ji","year":"2019","unstructured":"Ji Y, Yin Y, Li Z, Zhang W. Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD). Nutrients 2019;11(8):1712. https:\/\/doi.org\/10.3390\/nu11081712. (Epub 20190725)","journal-title":"Nutrients"},{"key":"10662_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594150","volume":"11","author":"S Mohammad","year":"2020","unstructured":"Mohammad S, Thiemermann C. Role of metabolic endotoxemia in systemic inflammation and potential interventions. Front Immunol 2020;11: 594150. https:\/\/doi.org\/10.3389\/fimmu.2020.594150. (Epub 20210111)","journal-title":"Front Immunol"},{"key":"10662_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.mam.2017.06.001","volume":"56","author":"M Li","year":"2017","unstructured":"Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver. Mol Aspects Med 2017;56:45\u201353. https:\/\/doi.org\/10.1016\/j.mam.2017.06.001. (Epub 20170701)","journal-title":"Mol Aspects Med"},{"issue":"7785","key":"10662_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","volume":"576","author":"S Hang","year":"2019","unstructured":"Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature 2019;576(7785):143\u2013148. https:\/\/doi.org\/10.1038\/s41586-019-1785-z. (Epub 20191127)","journal-title":"Nature"},{"issue":"1","key":"10662_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1042\/cs20220697","volume":"137","author":"J Gillard","year":"2023","unstructured":"Gillard J, Leclercq IA. Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease. Clin Sci (Lond) 2023;137(1):65\u201385. https:\/\/doi.org\/10.1042\/cs20220697","journal-title":"Clin Sci (Lond)"},{"key":"10662_CR43","doi-asserted-by":"publisher","first-page":"1089359","DOI":"10.3389\/fmolb.2022.1089359","volume":"9","author":"H Bing","year":"2022","unstructured":"Bing H, Li YL. The role of bile acid metabolism in the occurrence and development of NAFLD. Front Mol Biosci 2022;9:1089359. https:\/\/doi.org\/10.3389\/fmolb.2022.1089359. (Epub 20221215)","journal-title":"Front Mol Biosci"},{"key":"10662_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155583","volume":"144","author":"J Alharthi","year":"2023","unstructured":"Alharthi J, Pan Z, Gloss BS, McLeod D, Weltman M, George J, et al. Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. Metabolism 2023;144: 155583. https:\/\/doi.org\/10.1016\/j.metabol.2023.155583. (Epub 20230504)","journal-title":"Metabolism"},{"issue":"1","key":"10662_CR45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/ajg.2016.527","volume":"112","author":"CK Argo","year":"2017","unstructured":"Argo CK, Henry ZH. Editorial: \u201cLean\u201d NAFLD: metabolic obesity with normal BMI\u2026 is it in the genes? Am J Gastroenterol 2017;112(1):111\u2013113. https:\/\/doi.org\/10.1038\/ajg.2016.527","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10662_CR46","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","volume":"158","author":"M Krawczyk","year":"2020","unstructured":"Krawczyk M, Liebe R, Lammert F. Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond. Gastroenterology 2020;158(7):1865\u201380.e1. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.053. (Epub 20200215)","journal-title":"Gastroenterology"},{"issue":"1","key":"10662_CR47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/liv.15078","volume":"42","author":"H Lin","year":"2022","unstructured":"Lin H, Wong GL, Whatling C, Chan AW, Leung HH, Tse CH, et al. Association of genetic variations with NAFLD in lean individuals. Liver Int 2022;42(1):149\u2013160. https:\/\/doi.org\/10.1111\/liv.15078. (Epub 20211012)","journal-title":"Liver Int"},{"issue":"9","key":"10662_CR48","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/ajg.2015.235","volume":"110","author":"JL Wei","year":"2015","unstructured":"Wei JL, Leung JC, Loong TC, Wong GL, Yeung DK, Chan RS, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 2015;110(9):1306\u20131314. https:\/\/doi.org\/10.1038\/ajg.2015.235. (quiz 15; Epub 20150728)","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10662_CR49","doi-asserted-by":"publisher","first-page":"e0140427","DOI":"10.1371\/journal.pone.0140427","volume":"10","author":"K Nishioji","year":"2015","unstructured":"Nishioji K, Mochizuki N, Kobayashi M, Kamaguchi M, Sumida Y, Nishimura T, et al. The impact of PNPLA3 rs738409 genetic polymorphism and weight gain \u226510 kg after age 20 on non-alcoholic fatty liver disease in non-obese japanese individuals. PLoS ONE 2015;10(10):e0140427. https:\/\/doi.org\/10.1371\/journal.pone.0140427. (Epub 20151020)","journal-title":"PLoS ONE"},{"issue":"5","key":"10662_CR50","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s42255-019-0066-3","volume":"1","author":"A Yang","year":"2019","unstructured":"Yang A, Mottillo EP, Mladenovic-Lucas L, Zhou L, Granneman JG. Dynamic interactions of ABHD5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes. Nat Metab 2019;1(5):560\u2013569. https:\/\/doi.org\/10.1038\/s42255-019-0066-3. (Epub 20190506)","journal-title":"Nat Metab"},{"key":"10662_CR51","doi-asserted-by":"publisher","DOI":"10.5009\/gnl230044","author":"H Park","year":"2023","unstructured":"Park H, Yoon EL, Chung GE, Choe EK, Bae JH, Choi SH, et al. Genetic and metabolic characteristics of lean nonalcoholic fatty liver disease in a korean health examinee cohort. Gut Liver 2023. https:\/\/doi.org\/10.5009\/gnl230044. (Epub 20230810)","journal-title":"Gut Liver"},{"issue":"2","key":"10662_CR52","doi-asserted-by":"publisher","first-page":"194","DOI":"10.14218\/jcth.2020.00151","volume":"9","author":"WY Liu","year":"2021","unstructured":"Liu WY, Eslam M, Zheng KI, Ma HL, Rios RS, Lv MZ, et al. Associations of hydroxysteroid 17-beta dehydrogenase 13 variants with liver histology in chinese patients with metabolic-associated fatty liver disease. J Clin Transl Hepatol 2021;9(2):194\u2013202. https:\/\/doi.org\/10.14218\/jcth.2020.00151. (Epub 20210222)","journal-title":"J Clin Transl Hepatol"},{"key":"10662_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116770","volume":"481","author":"J Zhang","year":"2023","unstructured":"Zhang J, Ma S, Zhou W, Feng J, Kang Y, Yang W, et al. Genetic polymorphisms of CYP2B6 is a risk of metabolic associated fatty liver disease in Chinese population. Toxicol Appl Pharmacol 2023;481: 116770. https:\/\/doi.org\/10.1016\/j.taap.2023.116770. (Epub 20231122)","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"10662_CR54","doi-asserted-by":"publisher","first-page":"300060523118795","DOI":"10.1177\/03000605231187953","volume":"51","author":"X Yuan","year":"2023","unstructured":"Yuan X, Hou M, Wang Y, Zhang S, Li L, Mi Y, et al. Mitofusin-2 gene polymorphisms and metabolic dysfunction associated fatty liver disease: a case-control study in a Chinese population. J Int Med Res 2023;51(7):3000605231187953. https:\/\/doi.org\/10.1177\/03000605231187953","journal-title":"J Int Med Res"},{"issue":"5","key":"10662_CR55","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1007\/s12072-022-10371-2","volume":"16","author":"H Zeng","year":"2022","unstructured":"Zeng H, Tang C, Lin B, Yu M, Wang X, Wang J, et al. The regulation effect of GLUT9\/SLC2A9 on intrahepatic uric acid level and metabolic associated fatty liver disease. Hepatol Int 2022;16(5):1064\u20131074. https:\/\/doi.org\/10.1007\/s12072-022-10371-2. (Epub 20220825)","journal-title":"Hepatol Int"},{"issue":"1","key":"10662_CR56","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12916-022-02716-3","volume":"21","author":"GE Chung","year":"2023","unstructured":"Chung GE, Yu SJ, Yoo JJ, Cho Y, Lee KN, Shin DW, et al. Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease. BMC Med 2023;21(1):4. https:\/\/doi.org\/10.1186\/s12916-022-02716-3. (Epub 20230104)","journal-title":"BMC Med"},{"issue":"42","key":"10662_CR57","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.3748\/wjg.v26.i42.6514","volume":"26","author":"L Chrysavgis","year":"2020","unstructured":"Chrysavgis L, Ztriva E, Protopapas A, Tziomalos K, Cholongitas E. Nonalcoholic fatty liver disease in lean subjects: prognosis, outcomes and management. World J Gastroenterol 2020;26(42):6514\u20136528. https:\/\/doi.org\/10.3748\/wjg.v26.i42.6514","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10662_CR58","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/hep.0000000000000329","volume":"78","author":"O Nabi","year":"2023","unstructured":"Nabi O, Lapidus N, Boursier J, de Ledinghen V, Petit JM, Kab S, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology 2023;78(1):272\u2013283. https:\/\/doi.org\/10.1097\/hep.0000000000000329. (Epub 20230224)","journal-title":"Hepatology"},{"issue":"2","key":"10662_CR59","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11901-016-0302-1","volume":"15","author":"J Wattacheril","year":"2016","unstructured":"Wattacheril J, Sanyal AJ. Lean NAFLD: an underrecognized outlier. Curr Hepatol Rep 2016;15(2):134\u2013139. https:\/\/doi.org\/10.1007\/s11901-016-0302-1. (Epub 20160414)","journal-title":"Curr Hepatol Rep"},{"issue":"10","key":"10662_CR60","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","volume":"19","author":"M Eslam","year":"2022","unstructured":"Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol 2022;19(10):638\u2013651. https:\/\/doi.org\/10.1038\/s41575-022-00635-5. (Epub 20220616)","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10662_CR61","doi-asserted-by":"publisher","first-page":"101468","DOI":"10.1016\/j.diabet.2023.101468","volume":"49","author":"S Chen","year":"2023","unstructured":"Chen S, Xue H, Huang R, Chen K, Zhang H, Chen X. Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke. Diabetes Metab 2023;49(5):101468. https:\/\/doi.org\/10.1016\/j.diabet.2023.101468. (Epub 20230814)","journal-title":"Diabetes Metab"},{"issue":"1","key":"10662_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41387-023-00250-6","volume":"13","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, Yin Y, Deng Y. Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study. Nutr Diabetes 2023;13(1):21. https:\/\/doi.org\/10.1038\/s41387-023-00250-6. (Epub 20231115)","journal-title":"Nutr Diabetes"},{"issue":"5","key":"10662_CR63","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/jcsm.12754","volume":"12","author":"HS Chun","year":"2021","unstructured":"Chun HS, Kim MN, Lee JS, Lee HW, Kim BK, Park JY, et al. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle 2021;12(5):1168\u20131178. https:\/\/doi.org\/10.1002\/jcsm.12754. (Epub 20210801)","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10662_CR64","doi-asserted-by":"publisher","first-page":"1101892","DOI":"10.3389\/fendo.2023.1101892","volume":"14","author":"Y Yi","year":"2023","unstructured":"Yi Y, Wang C, Ding Y, He J, Lv Y, Chang Y. Diet was less significant than physical activity in the prognosis of people with sarcopenia and metabolic dysfunction-associated fatty liver diseases: Analysis of the National Health and Nutrition Examination Survey III. Front Endocrinol (Lausanne) 2023;14:1101892. https:\/\/doi.org\/10.3389\/fendo.2023.1101892. (Epub 20230223)","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"10662_CR65","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.3390\/ijms22115462","volume":"22","author":"S Fukunaga","year":"2021","unstructured":"Fukunaga S, Nakano D, Kawaguchi T, Eslam M, Ouchi A, Nagata T, et al. Non-obese MAFLD is associated with colorectal adenoma in health check examinees: a multicenter retrospective study. Int J Mol Sci 2021;22(11):5462. https:\/\/doi.org\/10.3390\/ijms22115462. (Epub 20210522)","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10662_CR66","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/hepr.13795","volume":"52","author":"S Fukunaga","year":"2022","unstructured":"Fukunaga S, Nakano D, Tsutsumi T, Kawaguchi T, Eslam M, Yoshinaga S, et al. Lean\/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis. Hepatol Res 2022;52(8):699\u2013711. https:\/\/doi.org\/10.1111\/hepr.13795. (Epub 20220607)","journal-title":"Hepatol Res"},{"key":"10662_CR67","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13973","author":"S Fukunaga","year":"2023","unstructured":"Fukunaga S, Mukasa M, Nakane T, Nakano D, Tsutsumi T, Chou T, et al. Impact of non-obese metabolic dysfunction-associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: a multicenter study. Hepatol Res 2023. https:\/\/doi.org\/10.1111\/hepr.13973. (Epub 20231005)","journal-title":"Hepatol Res"},{"issue":"6","key":"10662_CR68","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s12072-019-09982-z","volume":"13","author":"Q Wang","year":"2019","unstructured":"Wang Q, You H, Ou X, Zhao X, Sun Y, Wang M, et al. Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. Hepatol Int 2019;13(6):766\u2013776. https:\/\/doi.org\/10.1007\/s12072-019-09982-z. (Epub 20190926)","journal-title":"Hepatol Int"},{"issue":"12","key":"10662_CR69","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/jcm7120562","volume":"7","author":"L Denkmayr","year":"2018","unstructured":"Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, et al. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. J Clin Med 2018;7(12):562. https:\/\/doi.org\/10.3390\/jcm7120562. (Epub 20181217)","journal-title":"J Clin Med"},{"issue":"3","key":"10662_CR70","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3109\/00365521.2014.983160","volume":"50","author":"U Akyuz","year":"2015","unstructured":"Akyuz U, Yesil A, Yilmaz Y. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. Scand J Gastroenterol 2015;50(3):341\u2013346. https:\/\/doi.org\/10.3109\/00365521.2014.983160. (Epub 20141226)","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"10662_CR71","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/apt.17424","volume":"57","author":"K Wijarnpreecha","year":"2023","unstructured":"Wijarnpreecha K, Li F, Lundin SK, Suresh D, Song MW, Tao C, et al. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. Aliment Pharmacol Ther 2023;57(9):1014\u20131027. https:\/\/doi.org\/10.1111\/apt.17424. (Epub 20230223)","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10662_CR72","doi-asserted-by":"publisher","first-page":"e003066","DOI":"10.1136\/bmjdrc-2022-003066","volume":"11","author":"N Chen","year":"2023","unstructured":"Chen N, Zhou J, Wang K, Li X, Li Z. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus. BMJ Open Diabetes Res Care 2023;11(1):e003066. https:\/\/doi.org\/10.1136\/bmjdrc-2022-003066","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"10662_CR73","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00535-015-1127-3","volume":"51","author":"E Kumagai","year":"2016","unstructured":"Kumagai E, Korenaga K, Korenaga M, Imamura M, Ueyama M, Aoki Y, et al. Appropriate use of virtual touch quantification and FibroScan M and XL probes according to the skin capsular distance. J Gastroenterol 2016;51(5):496\u2013505. https:\/\/doi.org\/10.1007\/s00535-015-1127-3. (Epub 20151013)","journal-title":"J Gastroenterol"},{"issue":"6","key":"10662_CR74","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14(6):889\u2013919. https:\/\/doi.org\/10.1007\/s12072-020-10094-2. (Epub 20201001)","journal-title":"Hepatol Int"},{"issue":"6","key":"10662_CR75","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1097\/mcg.0000000000001089","volume":"53","author":"C Li","year":"2019","unstructured":"Li C, Guo P, Zhang R, Zhang M, Li Y, Huang M, et al. Both WHR and FLI as better algorithms for both lean and overweight\/obese NAFLD in a Chinese population. J Clin Gastroenterol 2019;53(6):e253\u2013e260. https:\/\/doi.org\/10.1097\/mcg.0000000000001089","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10662_CR76","doi-asserted-by":"publisher","first-page":"648","DOI":"10.4314\/ahs.v22i1.75","volume":"22","author":"D Ar\u0131kan","year":"2022","unstructured":"Ar\u0131kan D, \u00d6nmez A, Aksu E, Ta\u015fdemir N. Predictivity of fatty liver index for non-alcoholic fatty liver disease in lean females with polycystic ovary syndrome. Afr Health Sci 2022;22(1):648\u2013656. https:\/\/doi.org\/10.4314\/ahs.v22i1.75","journal-title":"Afr Health Sci"},{"issue":"5","key":"10662_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14309\/ctg.0000000000000042","volume":"10","author":"CL Hsu","year":"2019","unstructured":"Hsu CL, Wu FZ, Lin KH, Chen YH, Wu PC, Chen YH, et al. Role of fatty liver index and metabolic factors in the prediction of nonalcoholic fatty liver disease in a lean population receiving health checkup. Clin Transl Gastroenterol 2019;10(5):1\u20138. https:\/\/doi.org\/10.14309\/ctg.0000000000000042","journal-title":"Clin Transl Gastroenterol"},{"issue":"8","key":"10662_CR78","doi-asserted-by":"publisher","first-page":"e2329568","DOI":"10.1001\/jamanetworkopen.2023.29568","volume":"6","author":"H Park","year":"2023","unstructured":"Park H, Yoon EL, Ito T, Jo AJ, Kim M, Lee J, et al. Diagnostic performance of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in lean adults with nonalcoholic fatty liver disease. JAMA Netw Open 2023;6(8):e2329568. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.29568. (Epub 20230801)","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10662_CR79","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/meg.0000000000001946","volume":"34","author":"F Eren","year":"2022","unstructured":"Eren F, Kaya E, Yilmaz Y. Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals. Eur J Gastroenterol Hepatol 2022;34(1):98\u2013103. https:\/\/doi.org\/10.1097\/meg.0000000000001946","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10662_CR80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230x-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33. https:\/\/doi.org\/10.1186\/1471-230x-6-33. (Epub 20061102)","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"10662_CR81","doi-asserted-by":"publisher","first-page":"e070189","DOI":"10.1136\/bmjopen-2022-070189","volume":"13","author":"M Chang","year":"2023","unstructured":"Chang M, Shao Z, Shen G. Association between triglyceride glucose-related markers and the risk of metabolic-associated fatty liver disease: a cross-sectional study in healthy Chinese participants. BMJ Open 2023;13(5):e070189. https:\/\/doi.org\/10.1136\/bmjopen-2022-070189. (Epub 20230502)","journal-title":"BMJ Open"},{"issue":"12","key":"10662_CR82","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1016\/j.cgh.2019.09.027","volume":"18","author":"C Fu","year":"2020","unstructured":"Fu C, Wai JW, Nik Mustapha NR, Irles M, Wong GL, Mahadeva S, et al. Performance of simple fibrosis scores in nonobese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2020;18(12):2843\u20135.e2. https:\/\/doi.org\/10.1016\/j.cgh.2019.09.027. (Epub 20190928)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10662_CR83","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/liv.13983","volume":"39","author":"D Kim","year":"2019","unstructured":"Kim D, Kim W, Joo SK, Kim JH, Harrison SA, Younossi ZM, et al. Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. Liver Int 2019;39(2):332\u2013341. https:\/\/doi.org\/10.1111\/liv.13983. (Epub 20181027)","journal-title":"Liver Int"},{"key":"10662_CR84","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2019.181250","author":"J Yao","year":"2019","unstructured":"Yao J, Dai Y, Zhang J, Zhang X, Zheng R. Association between serum ferritin level and nonalcoholic fatty liver disease in a non-obese Chinese population: a cross-sectional study. Clin Lab 2019. https:\/\/doi.org\/10.7754\/Clin.Lab.2019.181250","journal-title":"Clin Lab"},{"issue":"12","key":"10662_CR85","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3390\/jpm12122009","volume":"12","author":"CH Xie","year":"2022","unstructured":"Xie CH, Chen LW, Lin CL, Hu CC, Chien CH. Serum uric acid but not ferritin level is associated with hepatic fibrosis in lean subjects with metabolic dysfunction-associated fatty liver disease: a community-based study. J Pers Med 2022;12(12):2009. https:\/\/doi.org\/10.3390\/jpm12122009. (Epub 20221203)","journal-title":"J Pers Med."},{"key":"10662_CR86","doi-asserted-by":"publisher","first-page":"1171397","DOI":"10.3389\/fendo.2023.1171397","volume":"14","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Zhuang X, Zhang J, Li M, Du S, Tian J, et al. Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease. Front Endocrinol (Lausanne) 2023;14:1171397. https:\/\/doi.org\/10.3389\/fendo.2023.1171397. (Epub 20231116)","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10662_CR87","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1053\/j.gastro.2022.08.004","volume":"164","author":"KZ Nadolsky","year":"2023","unstructured":"Nadolsky KZ. Use of the term \u201clean\u201d for nonalcoholic fatty liver disease in individuals with low body mass index. Gastroenterology 2023;164(3):502\u2013503. https:\/\/doi.org\/10.1053\/j.gastro.2022.08.004. (Epub 20220809)","journal-title":"Gastroenterology"},{"issue":"8","key":"10662_CR88","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/hepr.13906","volume":"53","author":"T Miwa","year":"2023","unstructured":"Miwa T, Francisque C, Tajirika S, Hanai T, Imamura N, Adachi M, et al. Impact of body fat accumulation on metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults. Hepatol Res 2023;53(8):691\u2013700. https:\/\/doi.org\/10.1111\/hepr.13906. (Epub 20230504)","journal-title":"Hepatol Res"},{"issue":"2","key":"10662_CR89","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12072-022-10439-z","volume":"17","author":"X Zhu","year":"2023","unstructured":"Zhu X, Huang Q, Ma S, Chen L, Wu Q, Wu L, et al. Presence of sarcopenia identifies a special group of lean NAFLD in middle-aged and older people. Hepatol Int 2023;17(2):313\u2013325. https:\/\/doi.org\/10.1007\/s12072-022-10439-z. (Epub 20221103)","journal-title":"Hepatol Int"},{"issue":"19","key":"10662_CR90","doi-asserted-by":"publisher","first-page":"12221","DOI":"10.3390\/ijerph191912221","volume":"19","author":"AL Ordo\u00f1ez-V\u00e1zquez","year":"2022","unstructured":"Ordo\u00f1ez-V\u00e1zquez AL, Ju\u00e1rez-Hern\u00e1ndez E, Zuarth-V\u00e1zquez JM, Ramos-Ostos MH, Uribe M, Castro-Narro G, et al. Impact on prevalence of the application of NAFLD\/MAFLD criteria in overweight and normal weight patients. Int J Environ Res Public Health 2022;19(19):12221. https:\/\/doi.org\/10.3390\/ijerph191912221. (Epub 20220927)","journal-title":"Int J Environ Res Public Health"},{"issue":"9","key":"10662_CR91","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14548","volume":"40","author":"S Lin","year":"2020","unstructured":"Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40(9):2082\u20132089. https:\/\/doi.org\/10.1111\/liv.14548. (Epub 20200726)","journal-title":"Liver Int"},{"issue":"10152","key":"10662_CR92","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/s0140-6736(18)31310-2","volume":"392","author":"MG Griswold","year":"2018","unstructured":"Griswold MG, Fullman N, Hawley C, Arian N, Zimsen SRM, Tymeson HD, et al. Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018;392(10152):1015\u20131035. https:\/\/doi.org\/10.1016\/s0140-6736(18)31310-2. (Epub 20180823)","journal-title":"Lancet"},{"issue":"2","key":"10662_CR93","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005.quize14-5","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149(2):367\u201378.e5. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005.quize14-5. (Epub 20150410)","journal-title":"Gastroenterology"},{"issue":"3","key":"10662_CR94","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","volume":"59","author":"VW Wong","year":"2013","unstructured":"Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2013;59(3):536\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2013.04.013. (Epub 20130423)","journal-title":"J Hepatol"},{"issue":"1S Suppl 1","key":"10662_CR95","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1097\/meg.0000000000002158","volume":"33","author":"DH Sinn","year":"2021","unstructured":"Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, et al. Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2021;33(1S Suppl 1):e529\u2013e534. https:\/\/doi.org\/10.1097\/meg.0000000000002158","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"10662_CR96","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/meg.0000000000001656","volume":"32","author":"P Hamurcu Varol","year":"2020","unstructured":"Hamurcu Varol P, Kaya E, Alphan E, Yilmaz Y. Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients. Eur J Gastroenterol Hepatol 2020;32(10):1352\u20131357. https:\/\/doi.org\/10.1097\/meg.0000000000001656","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10662_CR97","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","volume":"69","author":"VW Wong","year":"2018","unstructured":"Wong VW, Wong GL, Chan RS, Shu SS, Cheung BH, Li LS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol 2018;69(6):1349\u20131356. https:\/\/doi.org\/10.1016\/j.jhep.2018.08.011. (Epub 20180822)","journal-title":"J Hepatol"},{"issue":"7","key":"10662_CR98","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/liv.13435","volume":"37","author":"S Zelber-Sagi","year":"2017","unstructured":"Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: evidence and plausible mechanisms. Liver Int 2017;37(7):936\u2013949. https:\/\/doi.org\/10.1111\/liv.13435. (Epub 20170601)","journal-title":"Liver Int"},{"issue":"12","key":"10662_CR99","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3390\/biomedicines9121853","volume":"9","author":"C von Loeffelholz","year":"2021","unstructured":"von Loeffelholz C, Roth J, Coldewey SM, Birkenfeld AL. The role of physical activity in nonalcoholic and metabolic dysfunction associated fatty liver disease. Biomedicines 2021;9(12):1853. https:\/\/doi.org\/10.3390\/biomedicines9121853. (Epub 20211207)","journal-title":"Biomedicines."},{"issue":"1","key":"10662_CR100","doi-asserted-by":"publisher","first-page":"10977","DOI":"10.1038\/s41598-022-14701-0","volume":"12","author":"W Wang","year":"2022","unstructured":"Wang W, Ren J, Zhou W, Huang J, Wu G, Yang F, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study. Sci Rep 2022;12(1):10977. https:\/\/doi.org\/10.1038\/s41598-022-14701-0","journal-title":"Sci Rep"},{"issue":"1S Suppl 1","key":"10662_CR101","doi-asserted-by":"publisher","first-page":"e390-e4","DOI":"10.1097\/meg.0000000000002110","volume":"33","author":"H Guveli","year":"2021","unstructured":"Guveli H, Kenger EB, Ozlu T, Kaya E, Yilmaz Y. Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease: association between advanced fibrosis and high dietary intake of cholesterol\/saturated fatty acids. Eur J Gastroenterol Hepatol 2021;33(1S Suppl 1):e390\u2013e4. https:\/\/doi.org\/10.1097\/meg.0000000000002110","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"18","key":"10662_CR102","doi-asserted-by":"publisher","first-page":"6178","DOI":"10.1017\/s1368980021001762","volume":"24","author":"B Amirkalali","year":"2021","unstructured":"Amirkalali B, Khoonsari M, Sohrabi MR, Ajdarkosh H, Motamed N, Maadi M, et al. Relationship between dietary macronutrient composition and non-alcoholic fatty liver disease in lean and non-lean populations: a cross-sectional study. Public Health Nutr 2021;24(18):6178\u20136190. https:\/\/doi.org\/10.1017\/s1368980021001762. (Epub 20210426)","journal-title":"Public Health Nutr"},{"issue":"1","key":"10662_CR103","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","volume":"66","author":"R Hashida","year":"2017","unstructured":"Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol 2017;66(1):142\u2013152. https:\/\/doi.org\/10.1016\/j.jhep.2016.08.023. (Epub 20160914)","journal-title":"J Hepatol"},{"issue":"1","key":"10662_CR104","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/jgh.14360","volume":"34","author":"C Li","year":"2019","unstructured":"Li C, Guo P, Okekunle AP, Ji X, Huang M, Qi J, et al. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol 2019;34(1):256\u2013262. https:\/\/doi.org\/10.1111\/jgh.14360. (Epub 20180716)","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10662_CR105","doi-asserted-by":"publisher","first-page":"123","DOI":"10.14744\/hf.2023.2023.0034","volume":"4","author":"AS Kani","year":"2023","unstructured":"Kani AS, Ozercan A, Kani HT, Eren F, Sayar K, Yilmaz Y. Chronotype preference, sleep quality, and night-eating behaviors in patients with metabolic dysfunction-associated steatotic liver disease: assessing the relationship with disease severity and fibrosis. Hepatol Forum 2023;4(3):123\u2013128. https:\/\/doi.org\/10.14744\/hf.2023.2023.0034. (Epub 20230920)","journal-title":"Hepatol Forum"},{"issue":"5","key":"10662_CR106","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1017\/s0007114517000204","volume":"117","author":"F Mofidi","year":"2017","unstructured":"Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr 2017;117(5):662\u2013668. https:\/\/doi.org\/10.1017\/s0007114517000204. (Epub 20170327)","journal-title":"Br J Nutr"},{"issue":"4","key":"10662_CR107","doi-asserted-by":"publisher","first-page":"278","DOI":"10.5114\/ceh.2022.120099","volume":"8","author":"S Shinozaki","year":"2022","unstructured":"Shinozaki S, Tahara T, Miura K, Lefor AK, Yamamoto H. Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients. Clin Exp Hepatol 2022;8(4):278\u2013283. https:\/\/doi.org\/10.5114\/ceh.2022.120099. (Epub 20221129)","journal-title":"Clin Exp Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10662-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10662-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10662-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T18:07:03Z","timestamp":1727978823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10662-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":107,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10662"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10662-w","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"20 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nahum M\u00e9ndez-S\u00e1nchez, Willem Pieter Brouwer, Frank Lammert, Yusuf Yilmaz have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}